Associate Professor Will Herrington
Websites
- Medical Research Council Population Health Research Unit at the University of Oxford
-
Medical Research Council-UK
Professor David Kerr Clinician Scientist Award, 2018-2022
-
Kidney Research UK
Professor David Kerr Clinician Scientist Award, 2018-2022
- Health Data Research UK
-
British Heart Foundation
Centre of Research Excellence
- The EMPA-KIDNEY trial
- Mexico City Prospective Study
- The SHARP trial
- Cholesterol Treatment Trialists' Collaboration
- The UK-HARP3 trial
- The 3C trial
-
Oxford Kidney Unit
Honorary Consultant Nephrologist
-
Kidney Diseases: Improving Global Outcomes (KDIGO)
Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology
-
UK Renal Trials Network
Chair
Will Herrington
MA, MBBS, MD, FRCP
Associate Professor, Renal Studies Group
- Associate Professor, Renal Studies Group, MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Univ. of Oxford
- Honorary Consultant Nephrologist, Oxford Kidney Unit
BIOGRAPHY
Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He joined the Renal Studies Group as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). In 2013, he was awarded an MD from the University of Cambridge for a thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’.
He co-leads the EMPA-KIDNEY trial, which is testing the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. He also co-chairs the UK Kidney Association guideline working group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease, and has chaired the UK Renal Trials Network since 2020.
He also aims to better understand the key determinants of kidney disease development and progression using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease.